



PAEDIATRIC HYPERTENSION: ROLE IN GENETICS

Desai Avni P¹, Nishtha Jigneshkumar Desai², Nisarg Patel²

¹Assistant Professor, Department of Pharmaceutics, S.S.R. College of Pharmacy (Permanently Affiliated to Savitribai Phule Pune University), Sayli-Silvassa Road, Silvassa-396230, Union Territory of Dadra Nagar Haveli and Daman Diu, India.

²Smt. BNB Swaminarayan Pharmacy College, Salvaav, Vapi-396191, India.

Article DOI: <https://doi.org/10.36713/epra20074>

DOI No: 10.36713/epra20074

ABSTRACT

This essay reviews the genetic basis for both essential hypertension and normal blood pressure. There have been cases of familial aggregation of normal blood pressure in adults, children, and even new-borns. But the phenomena of blood pressure aggregation are a combination of shared environmental and hereditary elements. The investigations of blood pressure aggregation in twins and adopted kids were more specific for each etiological component. The Montreal Adoption Study was the centre of attention. Japanese research demonstrating the incidence of hypertension in children of hypertensive parents is reviewed in essential hypertension. The heterogeneity of essential hypertension is highlighted, and two of the several etiological factors the response to salt consumption and erythrocyte cation fluxes are specifically considered for their hereditary component. According to the assessment of the literature, essential hypertension is a polygenic illness that is spread through polygenic systems.

KEYWORDS: Blood Pressure, Hereditary, Hypertension, Illness, Genetics

INTRODUCTION

Blood pressure (BP) tracking phenomena suggests that children with elevated BP readings have a higher chance of developing hypertension (HT) as adults. Renovascular and renal parenchymal HT are highly prevalent in children with chronic kidney disease (CKD), which makes it significant that HT is also responsible for the advancement of renal impairment. It follows that early detection and intervention are crucial. Identifying the child with hypertension early on, determining the cause of the condition through specific studies, and developing treatment plans depending on the cause are all part of managing the young hypertensive.

Research on the heritability of blood pressure has shown that genetic variation accounts for 30–70% of the trait variance. Following the publication of several large-scale population genetic studies last year that surveyed a large number of stable genetic markers in an effort to associate individual markers with blood pressure and hypertension, the advancement of genetic investigation to identify the genes that contain this variation and thereby affect blood pressure regulation and influence the risk of hypertension has reached a new plateau. One significant technical accomplishment in the application of genome-wide association studies (GWAS) in populations is the ability to accurately type a very large number of single nucleotide polymorphisms (SNPs) in these individuals, amounting to hundreds of thousands. Large and well-characterized populations are also necessary. It is appropriate to examine how the current state of study into the genetics of high blood pressure was achieved, to explore the role that heritable factors continue to play in the mystery, and to consider the opportunities and challenges for future research.

Children's blood pressure reading accuracy and repeatability can be impacted by a variety of factors, including technical errors and reading variability. The distribution of blood pressure in a population is tilted to the right rather than following a symmetrical Gaussian distribution because life is incompatible below a certain blood pressure. It is now generally accepted that children with hypertension have blood pressure that consistently remains above the 95th percentile for their age, sex, and race. Children's hypertension was first arbitrarily defined as values at the upper end of the distribution curve.

In September 2017, the American Academy of Paediatricians (AAP) released their most recent recommendations for the diagnosis and treatment of HT in children and adolescents. These represent an update to the 2014 Fourth Report. Two major changes to these guidelines are the addition of new normative blood pressure tables based on the blood pressure values of children and adolescents of normal weight and the replacement of the term "pre-HT" with "elevated BP." The latter represents a modification from the tables in the Fourth Report, which also contained the blood pressure readings of those who were overweight or obese.

However, blood pressure is known to run in families, suggesting that genetics may be involved in how it is inherited. Furthermore, it has been demonstrated that a number of variables that control blood pressure are inherited. The genetic basis of both essential hypertension and normal blood pressure are reviewed in the current research. Consequently, the use of animal models of "genetic" hypertension has been a mainstay of hypertension research for more than thirty years. Genetic heterogeneity was resolved by creating fully inbred strains, and



it was believed that multifactorial interactions could be prevented by tightly regulating and controlling environmental factors. Recent advances in molecular genetics and theoretical concepts of quantitative trait analysis have been applied to these model systems in the hopes of elucidating at least some of the key genes that constitute the genetic basis for animal hypertension; however, there is no guarantee that analogies to human hypertension will follow.

It is supported by research on concordant and discordant twins, parent-offspring relationships, and natural-adopted children. The level of blood pressure was the phenotype used in these studies to identify the genetic component; however, the majority of the subjects had normal blood pressure and were under 40 years old.

We need to take into account the age-dependent nature of the environment's impact upon BP when reviewing the genetic and environmental components of total BP variation. For instance, it has been observed that early-life dietary salt intake has a significant impact on the subsequent blood pressure level in both humans and rats. Both in the short and long terms, normally infants are kept on a 6-month salt restriction having considerably lower blood pressure than infants on a normal sodium intake, even though both groups had been returned to the same sodium intake. Rats have also shown comparable findings, despite doubts about these results. Age-dependent changes in sodium intake have short-term blood pressure effects. In actuality, older individuals experience BP changes more dramatically than younger ones.

The molecular genetic approach (the Mendelian paradigm), which is used to study genes in individuals, and the phenomenological biometric approach (the Galton paradigm), which has been used to evaluate the genetic and environmental components of blood pressure in families. According to this approach, which measures blood pressure in related and unrelated individuals under random mating conditions, genetic (nature) and environmental (nurture) factors work together to cause hypertension. With this method, the percentage of total BP variance related to genetic (V_g) and environmental (V_e) factors is attempted to be determined. The literature reports values of V_g ranging from 20% to 55%. However, there are several issues when trying to connect these biometric values to more accurate molecular mechanisms of individual genetic makeup. Only in situations where genetic and environmental factors are unrelated to one another, the addition rule of variance ($V_t = V_g + V_e$) applies.

In humans, a low-salt diet produces a range of individual responses ranging from +17 mmHg to -15 mmHg, the average fall being -1.8 mmHg. When diuretics are administered, similar results are observed. Genetic variables account for a very large fraction of this variability, including the pressor effect, and this fraction will grow as our knowledge of the genetics behind this phenomenon deepens and the number of gene polymorphisms incorporated into the analysis increases. Consequently, only after gaining a thorough understanding of these events and carrying out the necessary measurements can the precise interplay between the genetic and environmental components be estimated.

Genetics of PAH

Pulmonary arterial hypertension (PAH) is a rare disease with an estimated prevalence of 4.8–8.1 cases/million for paediatric-onset and 15–50 cases/million for adult-onset disease. In addition to gene–environment interactions, which alter how genetic contributions to disease risk are influenced by environmental exposures, the disease is caused by genetic, epigenetic, and environmental variables. A number of significant factors, such as sex bias, clinical presentation, etiology, and therapeutic response, separate paediatric PAH from adult-onset illness. Females are more likely than males to experience adult-onset PAH, with a frequency that is approximately 3-5 times greater.

However, research in paediatric populations has been hampered by small sample sizes, highlighting the need for larger-scale studies to elucidate the genetic factors contributing to paediatric PAH.

Children's genetic base differs from adults in paediatric-onset PAH, according to emerging data from genetic investigations [10,11,13]. Compared to adult-onset PAH, which accounts for approximately 12.5% of cases, paediatric-onset PAH is caused by rare genetic variables, which indicate a higher genetic burden in children. De novo variations are common in children and probably account for about 15% of paediatric PAH cases.

Studies have identified mutations in genes such as *BMPR2*, *ACVRL1*, and *ENG* among paediatric PAH patients, with varying frequencies observed. For instance, one study found no *BMPR2* mutations in a cohort of children with IPAH, while another identified *BMPR2* and *ACVRL1* mutations in a subset of paediatric PAH patients. Additionally, *TBX4* mutations have been identified in paediatric PAH cases, potentially indicating a role in the condition's pathogenesis. Interestingly, some carriers of *TBX4* mutations also exhibited skeletal abnormalities suggestive of small patella syndrome (SPS).

Furthermore, novel missense mutations in genes like *BMPR1B* and *NOTCH3* have been reported in paediatric IPAH patients. These mutations affect signalling pathways involved in pulmonary hypertension development, suggesting their potential contribution to the disease phenotype in children.

Overall, while our understanding of the genetic basis of paediatric PAH is still evolving, these findings underscore the importance of further research to elucidate the complex genetic factors underlying this condition in children.

Variants that increase the risk of PAH

While the majority of IPAH cases have an unknown origin, common variations may increase the risk of the illness. Common polymorphisms in the cerebellum 2 gene that are linked to HPAH and IPAH were found in a large multinational genome-wide association investigation.

Genetic testing for PAH

Targeted sequencing and gene dosage analysis, such as multiplex ligation-dependent probe amplification, can be used simultaneously to perform genetic testing. In order to examine the complexity connected to genes with modest penetrance and



without currently known preventive interventions, genetic counselling for predictive testing have to be made available. Early diagnosis and treatment may be made possible for at-risk family members by patient education to guarantee awareness of illness signs and disease surveillance through echocardiograms every three years.

CONCLUSION

Compared to cohorts with adult onset of PAH, the yield of genetic diagnosis in paediatric-onset cohorts is much higher. Finding the genes, pathways, and networks in kids, however, may open up new therapeutic targets for all patients—including kids—who have PAH or are at high risk of developing it. Due to adult sexual dimorphism, inadequate penetrance, and genetic variability, the genetics of pulmonary hypertension are complicated. It is possible that there are yet unidentified genes, genetic, and environmental modifiers for PAH.

REFERENCES

1. Ward, R. (1990), "Familial aggregation and genetic epidemiology of blood pressure," in *Hypertension: Pathophysiology, Diagnosis and Management*, Vol. 1, edited by Laragh J.H. and Brenner B.M., New York, Raven Press, pp. 81–100.
2. Biron, P., Mongeau, J.G., Bertrand, D. (1976), "Familial aggregation of blood pressure in 588 adopted children," *Canadian Medical Association Journal*, 115, pp. 773–774.
3. Lifton, R.P., Gharavi, A.G., Geller, D.S. (2001), "Molecular mechanisms of human hypertension," *Cell*, 104, pp. 545–556.
4. Zinner, S.H., Levy, P.S., Kass, E.H. (1971), "Familial aggregation of blood pressure in childhood," *New England Journal of Medicine*, 284, pp. 401–404.
5. Levine, R.S., Heinekens, C.H., Perry, A., Cassady, J., Gelland, H., Jesse, M.J. (1982), "Genetic variance of blood pressure levels in infant twins," *American Journal of Epidemiology*, 116, pp. 759–764.
6. Moll, P.P., Harburg, E., Burns, T.L., Schork, M.A., Ozgoren, F. (1983), "Heredity, stress and blood pressure: A family set approach – The Detroit project revised," *Journal of Chronic Diseases*, 36, pp. 317–328.
7. Wolanski, N. (1969), "An approach to the problem of inheritance of systolic and diastolic blood pressure," *Genetica Polonica*, 10, pp. 263–268.
8. McIlhane, M.L., Shaffer, J.W., Hines, E.A. Jr. (1975), "The heritability of blood pressure: An investigation of 200 pairs of twins using the cold pressor test," *Johns Hopkins Medical Journal*, 36, pp. 57–74.
9. Feinleib, M., Garrison, R., Borhani, N. (1975), "Studies of hypertension in twins," in *Epidemiology and Control of Hypertension*, edited by Paul, O., New York, Stratton, pp. 3–20.
10. Li, L., Jick, S.S., Breitenstein, S., Hernandez, G., Michel, A., Vizcaya, D. (2017), "Pulmonary arterial hypertension in the USA: An epidemiological study in a large insured pediatric population," *Pulmonary Circulation*, 7, pp. 126–136.
11. Hansmann, G. (2017), "Pulmonary hypertension in infants, children, and young adults," *Journal of the American College of Cardiology*, 69, pp. 2551–2569.
12. Saji, T. (2013), "Update on pediatric pulmonary arterial hypertension: Differences and similarities to adult disease," *Circulation Journal*, 77, pp. 2639–2650.
13. Kerstjens-Frederikse, W.S., Bongers, E.M.H.F., Roofthoof, M.T.R., Leter, E.M., Douwes, J.M., Van Dijk, A., Vonk-Noordegraaf, A., Dijk-Bos, K.K., Hoefsloot, L.H., Hoendermis, E.S., et al. (2013), "TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension," *Journal of Medical Genetics*, 50, pp. 500–506.